{"id":64775,"date":"2025-02-18T12:01:34","date_gmt":"2025-02-18T12:01:34","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/02\/18\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/"},"modified":"2025-02-18T12:01:34","modified_gmt":"2025-02-18T12:01:34","slug":"bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/","title":{"rendered":"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA"},"content":{"rendered":"<div>\n<p align=\"center\">Company shares preliminary results from Phase 1\/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)<\/p>\n<p align=\"justify\">NEW YORK, Feb.  18, 2025  (GLOBE NEWSWIRE) &#8212; Bionic Sight, Inc., a company developing a novel gene therapy for retinal degenerative diseases, announced today that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational product BS01 for the treatment of retinitis pigmentosa (RP) patients with advanced stage vision loss.<\/p>\n<p align=\"justify\">RMAT designation is part of the 21st\u00a0Century Cures Act, which aims to accelerate the development of regenerative medicine therapies, including gene therapy, for serious medical conditions. RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with FDA, but is specified for regenerative medicine therapies. Bionic Sight is now preparing its Phase 3 program, as it advances toward marketing approval.<\/p>\n<p align=\"justify\">\u201cReceiving RMAT designation from the FDA is a significant validation of Bionic Sight\u2019s BS01 therapy, given the intensity of the FDA review process on both safety and efficacy data,\u201d said Calvin Roberts, MD, President and CEO of the Lighthouse Guild, an international organization for the blind. \u201cThe company has potentially game changing results for people with RP and the potential to have similar results for other retinal degenerative diseases as well.\u201d<\/p>\n<p align=\"justify\">The RMAT designation for BS01 was based on the preliminary data from Bionic Sight\u2019s ongoing first-in-human Phase 1\/2 clinical trial. Briefly, the participants who received the lower doses showed a modest but consistent improvement: 5 of 5 showed an increase in light sensitivity of 100-fold or more, and several also gained the ability to detect motion. The participants who received the two highest doses showed a much more marked improvement. Ten (10) of 11 showed an increase in visual acuity (Best Corrected Visual Acuity (BCVA)), with 7 patients showing an increase that was measurable on the EDTRS eye chart. The average increase for these 7 patients was nearly 5 lines on the eye chart (4.7 lines). This gain was seen across a spectrum of patients &#8212; from those whose baseline vision was at the \u201ccount fingers\u201d level to those whose baseline was at \u201ctunnel vision\u201d (less than 10 degrees of visual field, described by the patients as looking through a paper towel roll).\u00a0<\/p>\n<p align=\"justify\">In addition to the increase in BCVA, the \u201ccount fingers\u201d patients gained the ability to recognize shapes, objects, and, in some cases, colors, and the tunnel vision patients showed both an increase in visual field size (a 3-fold increase in area) and a pronounced improvement in their ability to navigate a maze (measured as a reduction in the time to complete the maze and a reduction in the number of errors). The remaining 3 high dose patients were at the \u201clight perception\u201d level at baseline; these participants improved to \u201chand motion\u201d. With respect to safety, BS01 was well-tolerated. No product-related serious events occurred; all events were grade 1 or 2 and generally asymptomatic.<\/p>\n<p align=\"justify\">Bionic Sight\u2019s Phase 1\/2 trial (ClinicalTrials.gov identifier:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IU9rE2xn0hUz8Re4MKxPBC9Zns9xerJUGYaM0oZ8OuhISytDcPaZPtBZg5cinRLpjehlzSms7P3vFxs6MfLksYTS6TooqIhCiUFKe0YSJis8Yw0Kn1wrfiqb-PsMS0RlpFlCI8g6AMAoHDKyp8pHC0rEE72tUUFIKbumsJBjFrJdl3dU9cuSjrKMsE3yL9B5BR96Hwo-wGU9I6bFhmxPN-kAJwg-gpy94QOgjCHyicB7SfdVCU_3Y6sAk0AxdAHzb2WK3wAyxGm0clY-llQGjRff_YfY8-qwzuHQW_V6MLn9lUBM9glKzbDtB9aNYBqTlvf8rW-L8__SOcnSwdokPaW2vZgHeLtl4RhisSfHW_U=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>NCT04278131<\/u><\/a>) is an ongoing open-label, dose escalation study in patients with advanced-stage RP. The primary focus of the study is to assess the safety of BS01 through analysis of ocular or systemic treatment-related adverse events. Efficacy is measured by assessing the detection of light, BCVA, shape\/object\/color recognition, and maze navigation.<\/p>\n<p align=\"justify\"><strong>About the Company<\/strong><br \/>Bionic Sight, Inc. is a biotech company that develops gene therapy vectors and devices to treat retinal degenerative diseases. The company was founded by Dr. Sheila Nirenberg, a professor at the Weill Medical College of Cornell University, and builds on her lab\u2019s work on retinal and neuro-degenerative diseases and computer vision. Her work on deciphering the retina\u2019s neural code and using it to restore visual function earned her a MacArthur \u201cgenius\u201d award. For more information on the company, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x_Mx0twllYXjBfeSuK73prmFtiCdsSKttp1oR7pQIm_w36QhP0hdu9_03hFWrXHcEGSTx8WbKJZTcFFjlX7lgBmmJgShodws0y_KZZACZaWtV8_i0IcToJ_thuInTRF7ilqILwuuu1_WqxaPoMt0isYfXpla8LXWUujuTxteKzcHIcLxolIpOoXoyCKfokIFfohYli7HRHe6ddnba1Ag45qjagPthXeFnK4HjjJhs-lYz_d7V37pCjVPW4x2APE8l0HDvwRoKwQ1U3Lr5uFKsXRTDHDKt6AvnwHTXe6RyAUJJZYcQrG1WLGMmnY6CeBz\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.bionicsightllc.com<\/u><\/a>.<\/p>\n<p align=\"justify\"><strong>IR and PR Contacts:<\/strong><br \/>Sheila Nirenberg, PhD <br \/>Founder<br \/>Bionic Sight, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YjN4U5ij9ru_Nfc9uqzAIX-YYjEZoMv55EtwjfLfeCzczMju4yVI56-XGq2tzZfMwor4TPvRJ9sE6EYepoPN1SeMoPdHnIRdEZK2bHrxW4Uy8l0Bh1eKQ_QsTuHH6kcK\" rel=\"nofollow\" target=\"_blank\" title=\"snirenberg@bionic-sight.com\">snirenberg@bionic-sight.com<\/a><\/p>\n<p align=\"justify\">Adam Carte<br \/>Business Development<br \/>Bionic Sight, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5B6vRiZ6Zca-X3osXe35ZxoCMnAOeeGrwoa2Xkbo2MG5dN06rEe_FD4_nOVGwsfHERfBGVSVXbgeK0SI64m4mvepUdgviNNEt-5NXRFNpgFm9_xVQiYU0M5geOW9Mtmi\" rel=\"nofollow\" target=\"_blank\" title=\"acarte@fairleadadvisors.com\">acarte@fairleadadvisors.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmVjODNkMzEtZjVkZS00MjJmLWE4YTQtYWM3YzAzYWMzNzgxLTEzMTAxMjU=\/tiny\/Bionic-Sight-LLC.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company shares preliminary results from Phase 1\/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP) NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Bionic Sight, Inc., a company developing a novel gene therapy for retinal degenerative diseases, announced today that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational product BS01 [&#8230;]\n","protected":false},"author":1,"featured_media":64776,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-64775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA\" \/>\n<meta property=\"og:description\" content=\"Company shares preliminary results from Phase 1\/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP) NEW YORK, Feb. 18, 2025 (GLOBE N\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T12:01:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/02\/Bionic-Sight-LLC.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA\",\"datePublished\":\"2025-02-18T12:01:34+00:00\",\"dateModified\":\"2025-02-18T12:01:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\"},\"wordCount\":650,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\",\"name\":\"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-02-18T12:01:34+00:00\",\"dateModified\":\"2025-02-18T12:01:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/","og_locale":"en_US","og_type":"article","og_title":"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA","og_description":"Company shares preliminary results from Phase 1\/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP) NEW YORK, Feb. 18, 2025 (GLOBE N","og_url":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-02-18T12:01:34+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/02\/Bionic-Sight-LLC.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA","datePublished":"2025-02-18T12:01:34+00:00","dateModified":"2025-02-18T12:01:34+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/"},"wordCount":650,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/","url":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/","name":"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-02-18T12:01:34+00:00","dateModified":"2025-02-18T12:01:34+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/bionic-sights-bs01-gene-therapy-receives-rmat-designation-from-the-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Bionic Sight\u2019s BS01 Gene Therapy Receives RMAT Designation from the FDA"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=64775"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64775\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/64776"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=64775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=64775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=64775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}